MY207759A - Pharmaceutical drug containing heterocyclidene acetamide derivative - Google Patents
Pharmaceutical drug containing heterocyclidene acetamide derivativeInfo
- Publication number
- MY207759A MY207759A MYPI2022001736A MYPI2022001736A MY207759A MY 207759 A MY207759 A MY 207759A MY PI2022001736 A MYPI2022001736 A MY PI2022001736A MY PI2022001736 A MYPI2022001736 A MY PI2022001736A MY 207759 A MY207759 A MY 207759A
- Authority
- MY
- Malaysia
- Prior art keywords
- drug containing
- pharmaceutical drug
- acetamide derivative
- dry eye
- heterocyclidene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019184053 | 2019-10-04 | ||
| PCT/JP2020/037548 WO2021066144A1 (ja) | 2019-10-04 | 2020-10-02 | ヘテロシクリデンアセトアミド誘導体含有医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY207759A true MY207759A (en) | 2025-03-17 |
Family
ID=75338162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2022001736A MY207759A (en) | 2019-10-04 | 2020-10-02 | Pharmaceutical drug containing heterocyclidene acetamide derivative |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12533337B2 (https=) |
| EP (2) | EP4545095A3 (https=) |
| JP (4) | JP7025094B2 (https=) |
| KR (1) | KR20220078604A (https=) |
| CN (1) | CN114585357A (https=) |
| AU (1) | AU2026202464A1 (https=) |
| BR (1) | BR112022005992A2 (https=) |
| CA (1) | CA3156484A1 (https=) |
| DK (1) | DK4043014T3 (https=) |
| ES (1) | ES3031607T3 (https=) |
| HU (1) | HUE072085T2 (https=) |
| MX (2) | MX2022004027A (https=) |
| MY (1) | MY207759A (https=) |
| PH (1) | PH12022550805A1 (https=) |
| PL (1) | PL4043014T3 (https=) |
| PT (1) | PT4043014T (https=) |
| WO (1) | WO2021066144A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3156484A1 (en) | 2019-10-04 | 2021-04-08 | Senju Pharmaceutical Co., Ltd. | PHARMACEUTICAL MEDICINAL PRODUCT CONTAINING A HETEROCYCLIDENE ACETAMIDE DERIVATIVE |
| CN117120048A (zh) | 2021-03-30 | 2023-11-24 | 千寿制药株式会社 | 含杂环亚基乙酰胺衍生物的悬浮液 |
| KR20250065723A (ko) | 2022-09-29 | 2025-05-13 | 센주 세이야꾸 가부시키가이샤 | 멸균 처리한 헤테로시클리덴아세트아미드 유도체 함유 현탁액 |
| JP7589394B2 (ja) * | 2022-09-29 | 2024-11-25 | 千寿製薬株式会社 | ヘテロシクリデンアセトアミド誘導体を含む配合剤 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5621566A (en) | 1979-08-01 | 1981-02-28 | Alpha- Shokuhin Kk | Preparation of bifun from homegrown rice and apparatus used for it |
| CN101228131B (zh) * | 2005-07-22 | 2013-01-09 | 持田制药株式会社 | 新的杂环亚基乙酰胺衍生物 |
| JP4754566B2 (ja) | 2005-07-22 | 2011-08-24 | 持田製薬株式会社 | 新規なヘテロシクリデンアセトアミド誘導体 |
| RU2451014C2 (ru) | 2005-07-22 | 2012-05-20 | Мотида Фармасьютикал Ко., Лтд. | Новое производное гетероциклиден ацетамида |
| TW200927192A (en) | 2007-11-19 | 2009-07-01 | Alcon Res Ltd | Use of TRPV1 receptor antagonists for treating dry eye and ocular pain |
| US20100210682A1 (en) * | 2009-02-19 | 2010-08-19 | Abbott Laboratories | Repeated Dosing of TRPV1 Antagonists |
| EP2377850A1 (en) | 2010-03-30 | 2011-10-19 | Pharmeste S.r.l. | TRPV1 vanilloid receptor antagonists with a bicyclic portion |
| WO2012045729A1 (en) * | 2010-10-05 | 2012-04-12 | Glaxo Group Limited | Imidazo [1, 2 -a] pyridine and pyrazolo [1, 5 -a] pyridine derivatives as trpv1 antagonists |
| GB201215857D0 (en) * | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| JP6230743B1 (ja) * | 2017-05-31 | 2017-11-15 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の結晶 |
| JP7373909B2 (ja) | 2018-04-06 | 2023-11-06 | 株式会社シマノ | 変速制御装置および変速システム |
| CA3156484A1 (en) | 2019-10-04 | 2021-04-08 | Senju Pharmaceutical Co., Ltd. | PHARMACEUTICAL MEDICINAL PRODUCT CONTAINING A HETEROCYCLIDENE ACETAMIDE DERIVATIVE |
-
2020
- 2020-10-02 CA CA3156484A patent/CA3156484A1/en active Pending
- 2020-10-02 PH PH1/2022/550805A patent/PH12022550805A1/en unknown
- 2020-10-02 CN CN202080069192.5A patent/CN114585357A/zh active Pending
- 2020-10-02 MY MYPI2022001736A patent/MY207759A/en unknown
- 2020-10-02 JP JP2021541679A patent/JP7025094B2/ja active Active
- 2020-10-02 KR KR1020227012080A patent/KR20220078604A/ko active Pending
- 2020-10-02 PL PL20872061.5T patent/PL4043014T3/pl unknown
- 2020-10-02 PT PT208720615T patent/PT4043014T/pt unknown
- 2020-10-02 WO PCT/JP2020/037548 patent/WO2021066144A1/ja not_active Ceased
- 2020-10-02 EP EP25164201.3A patent/EP4545095A3/en active Pending
- 2020-10-02 DK DK20872061.5T patent/DK4043014T3/da active
- 2020-10-02 EP EP20872061.5A patent/EP4043014B1/en active Active
- 2020-10-02 MX MX2022004027A patent/MX2022004027A/es unknown
- 2020-10-02 HU HUE20872061A patent/HUE072085T2/hu unknown
- 2020-10-02 BR BR112022005992A patent/BR112022005992A2/pt unknown
- 2020-10-02 ES ES20872061T patent/ES3031607T3/es active Active
- 2020-10-02 US US17/766,090 patent/US12533337B2/en active Active
-
2022
- 2022-02-07 JP JP2022017196A patent/JP7248836B2/ja active Active
- 2022-04-01 MX MX2025005474A patent/MX2025005474A/es unknown
- 2022-10-26 JP JP2022171542A patent/JP7801201B2/ja active Active
-
2025
- 2025-01-03 US US19/009,260 patent/US12502375B2/en active Active
-
2026
- 2026-01-05 JP JP2026000075A patent/JP2026042857A/ja active Pending
- 2026-03-31 AU AU2026202464A patent/AU2026202464A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022065024A (ja) | 2022-04-26 |
| EP4043014A4 (en) | 2023-10-11 |
| WO2021066144A1 (ja) | 2021-04-08 |
| CA3156484A1 (en) | 2021-04-08 |
| EP4545095A2 (en) | 2025-04-30 |
| US12502375B2 (en) | 2025-12-23 |
| PH12022550805A1 (en) | 2023-10-02 |
| JPWO2021066144A1 (ja) | 2021-12-02 |
| DK4043014T3 (da) | 2025-06-23 |
| HUE072085T2 (hu) | 2025-10-28 |
| JP7248836B2 (ja) | 2023-03-29 |
| MX2025005474A (es) | 2025-06-02 |
| US20220370404A1 (en) | 2022-11-24 |
| EP4043014B1 (en) | 2025-03-19 |
| US20250134854A1 (en) | 2025-05-01 |
| AU2020361093A1 (en) | 2022-05-19 |
| MX2022004027A (es) | 2022-07-19 |
| JP2023011735A (ja) | 2023-01-24 |
| JP7801201B2 (ja) | 2026-01-16 |
| PT4043014T (pt) | 2025-06-09 |
| AU2026202464A1 (en) | 2026-04-16 |
| KR20220078604A (ko) | 2022-06-10 |
| PL4043014T3 (pl) | 2025-08-11 |
| CN114585357A (zh) | 2022-06-03 |
| US12533337B2 (en) | 2026-01-27 |
| ES3031607T3 (en) | 2025-07-09 |
| EP4545095A3 (en) | 2025-07-02 |
| BR112022005992A2 (pt) | 2022-06-21 |
| JP2026042857A (ja) | 2026-03-11 |
| EP4043014A1 (en) | 2022-08-17 |
| JP7025094B2 (ja) | 2022-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025005474A (es) | Farmaco farmaceutico que contiene derivado de heterocicliden acetamida | |
| EP3569601A3 (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| CY1124432T1 (el) | Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη | |
| MX2022006865A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio. | |
| PY2054376A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
| EP4563150A3 (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer | |
| MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
| MY208983A (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
| MX2021010115A (es) | Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda. | |
| MX2020011089A (es) | Compuestos antiproliferacion y usos de los mismos. | |
| PH12020551772A1 (en) | Oxo-substituted compound | |
| MX2021005944A (es) | Inhibidores de rip1. | |
| PH12019500327A1 (en) | Indazole compounds for use in tendon and/or ligament injuries | |
| MX2021001349A (es) | Un nuevo tratamiento medico para la inflamacion patologica. | |
| PH12020500228A1 (en) | Pharmacutical composition comprising remogliflozin and antidiabetic agent | |
| MX2016009226A (es) | Combinaciones farmaceuticas. | |
| BR112018002138A2 (pt) | composto 2-(5 s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida, uso, composição farmacêutica e método para a profilaxia ou o tratamento de convulsões | |
| MX2022006180A (es) | Derivados macrociclicos de sulfonilo como inhibidores de mcl-1. | |
| AR109457A1 (es) | Método para el tratamiento de la ame y composición farmacéutica | |
| PH12021552886A1 (en) | Pyrido-pyrimidin derivatives and pharmaceutical composition, for use in preventing or treating pi3 kinase related diseases, comprising same as active ingredient | |
| MX2021004997A (es) | Tratamiento y prevencion de la eyaculacion precoz (ep). | |
| CL2021001322A1 (es) | Inhibidores de rip1 | |
| NZ752587B2 (en) | Lsd1 inhibitors and medical uses thereof | |
| EA202090298A1 (ru) | Способы лечения муковисцидоза |